Cargando…

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

BACKGROUND: The anticancer properties of metformin have been suggested in numerous experimental studies and several retrospective clinical studies show that its use is associated with improved outcome of patients with cancer. However, limited data are available for patients with metastatic renal cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiala, Ondřej, Ostašov, Pavel, Rozsypalová, Aneta, Hora, Milan, Šorejs, Ondřej, Šustr, Jan, Bendová, Barbora, Trávníček, Ivan, Filipovský, Jan, Fínek, Jindřich, Büchler, Tomáš
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153069/ https://www.ncbi.nlm.nih.gov/pubmed/34054309 http://dx.doi.org/10.2147/CMAR.S305321

Ejemplares similares

Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
por: Fiala, Ondrej, et al.
Publicado: (2019)

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line
por: Fiala, Ondrej, et al.
Publicado: (2018)

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
por: Fiala, Ondrej, et al.
Publicado: (2020)

Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection
por: Kolenčík, Drahomír, et al.
Publicado: (2022)

An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis
por: Windrichova, Jindra, et al.
Publicado: (2018)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
por: Novakova-Jiresova, Alena, et al.
Publicado: (2020)

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
por: Slavicek, Lubomir, et al.
Publicado: (2014)

Laparoscopic adrenalectomy for metachronous ipsilateral metastasis following nephrectomy for renal cell carcinoma
por: Stránský, Petr, et al.
Publicado: (2013)

Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma
por: Tesarova, Tereza, et al.
Publicado: (2023)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry
por: Pavlík, Tomáš, et al.
Publicado: (2012)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Position of laparo-endoscopic single-site surgery nephrectomy in clinical practice and comparison (matched case-control study) with standard laparoscopic nephrectomy
por: Hora, Milan, et al.
Publicado: (2014)

Complete laparoscopic nephroureterectomy with intravesical lockable clip
por: Hora, Milan, et al.
Publicado: (2012)

Surgical treatment of kidney tumors – contemporary trends in clinical practice
por: Hora, Milan, et al.
Publicado: (2016)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

Managing urine leakage following laparoscopic radical prostatectomy with active suction of the prevesical space
por: Hora, Milan, et al.
Publicado: (2012)

MiT translocation renal cell carcinomas: two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]
por: Hora, Milan, et al.
Publicado: (2014)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

VEILND (Video Endoscopic Inguinal Lymph Node Dissection) with Florescence Indocyanine Green (ICG): A Novel Technique to Identify the Sentinel Lymph Node in Men with ≥pT1G2 and cN0 Penile Cancer
por: Hora, Milan, et al.
Publicado: (2021)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
por: Bouchalova, Pavla, et al.
Publicado: (2021)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Laparoscopic urinary bladder diverticulectomy combined with photoselective vaporisation of the prostate
por: Hora, Milan, et al.
Publicado: (2015)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ue18padgjsgqpa2pjai6u2cqbr